Rpo LLC Takes $42,000 Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Rpo LLC purchased a new stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 66,378 shares of the company’s stock, valued at approximately $42,000.

A number of other large investors have also added to or reduced their stakes in LYEL. Centiva Capital LP bought a new stake in Lyell Immunopharma during the third quarter worth $31,000. Intech Investment Management LLC acquired a new position in shares of Lyell Immunopharma during the 3rd quarter worth $52,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Lyell Immunopharma during the 3rd quarter worth $52,000. Erste Asset Management GmbH bought a new stake in shares of Lyell Immunopharma during the 3rd quarter worth $82,000. Finally, SG Americas Securities LLC boosted its stake in Lyell Immunopharma by 102.8% in the fourth quarter. SG Americas Securities LLC now owns 116,748 shares of the company’s stock valued at $75,000 after buying an additional 59,182 shares in the last quarter. Institutional investors and hedge funds own 66.05% of the company’s stock.

Lyell Immunopharma Stock Performance

Shares of NASDAQ:LYEL opened at $0.51 on Thursday. Lyell Immunopharma, Inc. has a 52-week low of $0.48 and a 52-week high of $3.15. The company has a market capitalization of $149.83 million, a PE ratio of -0.64 and a beta of -0.41. The company has a fifty day moving average of $0.61 and a 200-day moving average of $0.85.

Lyell Immunopharma (NASDAQ:LYEL) last issued its earnings results on Wednesday, March 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.52). Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. The firm had revenue of $0.01 million during the quarter. On average, equities analysts forecast that Lyell Immunopharma, Inc. will post -0.78 EPS for the current fiscal year.

Insider Activity at Lyell Immunopharma

In related news, CEO Lynn Seely bought 175,000 shares of the stock in a transaction that occurred on Friday, March 14th. The stock was acquired at an average cost of $0.61 per share, with a total value of $106,750.00. Following the transaction, the chief executive officer now directly owns 712,500 shares in the company, valued at approximately $434,625. This trade represents a 32.56 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Sumant Ramachandra bought 200,000 shares of the business’s stock in a transaction on Friday, March 21st. The shares were bought at an average cost of $0.58 per share, for a total transaction of $116,000.00. Following the completion of the acquisition, the director now directly owns 200,000 shares in the company, valued at approximately $116,000. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders acquired a total of 768,640 shares of company stock worth $449,508 in the last quarter. 25.10% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “neutral” rating and set a $1.00 target price on shares of Lyell Immunopharma in a research note on Thursday, March 13th.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.